A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Indoles
  • Prostatic Neoplasms

abstract

  • Despite promising preclinical data and scientific rationale, treatment with IV panobinostat did not show a sufficient level of clinical activity to pursue further investigation as a single agent in CRPC.

publication date

  • September 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3970811

Digital Object Identifier (DOI)

  • 10.1007/s00280-013-2224-8

PubMed ID

  • 23820963

Additional Document Info

start page

  • 537

end page

  • 44

volume

  • 72

number

  • 3